Rapport Therapeutics, Inc. (RAPP)
Nasdaq: RAPP · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2024
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 10, 2026 | Mar 11, 2025 | · |
| Research and development | 94,789 | 60,935 | 27,999 |
| General and administrative | 30,310 | 22,120 | 8,180 |
| Total operating expenses | 125,099 | 83,055 | 36,179 |
| Operating income | -125,099 | -83,055 | -36,179 |
| Interest and investment income | 13,616 | 12,138 | 2,527 |
| Total non-operating income (expense) | 13,616 | 4,748 | 1,403 |
| Income before income taxes | · | -78,307 | -34,776 |
| Income tax expense | 0 | 0 | 10 |
| Net income including non-controlling interests | -111,483 | -78,307 | -34,786 |
| Net income | -111,483 | -78,307 | -34,786 |
| Net income to common shareholders | -111,483 | -78,307 | -34,786 |
| Earnings per share, basic | -2.86 | -3.78 | -23.10 |
| Earnings per share, diluted | -2.86 | -3.78 | -23.10 |
| Weighted average shares, basic | 38,934,569 | 20,738,338 | 1,505,774 |
| Weighted average shares, diluted | 38,934,569 | 20,738,338 | 1,505,774 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding